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Background: The human a-interferon (huIFN-a) family displays broad spectrum
antiviral, antiproliferative and immunomodulatory activities on a variety of cell
types. The diverse biological activities of the IFN-a’s are conveyed to cells
through specific interactions with cell-surface receptors. Despite considerable
effort, no crystal structure of a member of this family has yet been reported,
because the quality of the protein crystals have been unsuitable for
crystallographic studies. Until now, structural models of the IFN-a’s have been
based on the structure of murine IFN-b (muIFN-b). These models are likely to be
inaccurate, as the amino acid sequence of muIFN-b differs significantly from the
IFN-a’s at proposed receptor-binding sites. Structural information on a huIFN-a
subtype would provide an improved basis for modeling the structures of the
entire IFN-a family.
Results: The crystal structure of recombinant human interferon-a2b (huIFN-a2b)
has been determined at 2.9 Å resolution. HuIFN-a2b exists in the crystal as a
noncovalent dimer, which associates in a novel manner. Unlike other structurally
characterized cytokines, extensive interactions in the dimer interface are
mediated by a zinc ion (Zn2+). The overall fold of huIFN-a2b is most similar to the
structure of muIFN-b. Unique to huIFN-a2b is a 310 helix in the AB loop which is
held to the core of the molecule by a disulfide bond.
Conclusions: The structure of huIFN-a2b provides an accurate model for
analysis of the >15 related type I interferon molecules. HuIFN-a2b displays
considerable structural similarity with muIFN-b, interleukin-10 and interferon-g,
which also bind related class 2 cytokine receptors. From these structural
comparisons and numerous studies on the effects of mutations on biological
activity, we have identified protein surfaces that appear to be important in
receptor activation. This study also reveals the potential biological importance of
the huIFN-a2b dimer.
Introduction
The human a-interferons (huIFN-a’s) are encoded by a
family of at least 15 intronless genes which are differentially
expressed by cells in response to a variety of infectious
agents [1,2]. Although originally discovered for their broad
spectrum antiviral properties, IFN-a’s also have antiprolif-
erative and immunomodulatory effects on a variety of cell
types [3]. The practical importance of these pleiotropic
activities is shown by the approval of recombinant huIFN-
a2b (Intron A) for the treatment of >14 diseases world-wide,
including hairy-cell leukemia, condyloma acuminatum,
Kaposi’s sarcoma, and hepatitis [4,5].
The diverse biological activities of IFN-a’s are conveyed to
cells through specific interactions with cell-surface recep-
tors. Although the components of the IFN-a signaling
complex are still being defined, two distinct receptor pro-
teins have been cloned and characterized (IFN-aR1 
[6] and IFN-a/bR [7]). Because the IFN-a/bR can bind
several IFN-a subtypes as well as IFN-b, it appears to
be the major ligand-binding component of the receptor
complex. In contrast, the IFN-aR1, which is required for
IFN-a/IFN-b signaling, can only bind to IFN-a8 [8]. The
IFN-aR1 seems to have a complementary role in ligand
binding, as it increases the affinity of the receptor for the
ligand by ~10-fold [9]. The observed properties of the 
two receptors seem to be consistent with the idea that 
the receptors bind to IFN-a sequentially; first IFN-a/bR
and then IFN-aR1. Such stepwise binding is observed 
in better characterized cytokine signaling systems [10].
Sequence comparisons reveal that IFN-aR1 and IFN-a/bR
are both members of the class 2 cytokine receptor family
which includes the receptors for interferon-g (IFN-g), inter-
leukin-10 (IL-10), and tissue factor [11]. The extracellular
portions of the receptors should therefore resemble the
crystal structure of the IFN-g receptor [12], which contains
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two fibronectin type III domains with an angle between
them of ~120°. The longer extracellular sequence of the
IFN-aR1 (~400 amino acids versus ~200 amino acids for the
IFN-gRa, and IFN-a/bR) is likely to contain two putative
class 2 ligand binding domains linked in tandem. The intra-
cellular domains of the IFN-a/bR and IFN-aR1 are associ-
ated with the Jak-1 and Tyk-2 kinases, respectively [7,13].
Characterization of the individual IFN-a gene products
revealed mature proteins of 165 (IFN-a2) or 166 (all other
IFNa’s) amino acids in length. All a-interferon species
have two conserved disulfide bonds; Cys1–Cys98 and
Cys29–Cys138 [14]. Despite sharing ~80% sequence iden-
tity (IFN-a1 and IFN-a2 differ at only 28 amino acid posi-
tions), each IFN-a subspecies elicits different levels of
antiviral and antiproliferative responses on various cells
[15]. From their biophysical properties, the a-interferons
form part of the type I interferon family, which also
includes IFN-b and IFN-v [16,17]. Although the IFN-a’s
are encoded by a multigene family, only one gene for IFN-
b has been identified. The amino acid sequences of IFN-
a and IFN-b are ~50% homologous [18]. Based on the
crystal structure of muIFN-b [19], the type I interferons
were classified as members of the longchain cytokine
family [20]. IFN-g, the only type II interferon, and
muIFN-b share virtually no sequence homology, but have
related three-dimensional structures [21].
Efforts to elucidate the three-dimensional structure of the
IFN-a’s by X-ray diffraction have been hampered by the
lack of high-quality crystals, although small crystals were
first reported 14 years ago [22]. The crystal structure of
muIFN-b has therefore been used for homology modeling
of the IFN-a’s [23]. Although useful, these models are
inevitably inaccurate due to significant amino acid dif-
ferences between the IFN-a’s and muIFN-b in biologically
important loops. Furthermore, the original coordinates of
muIFN-b contained several errors which have only recently
been corrected by high resolution refinement [19]. Here 
we report the 2.9Å structure of recombinant human zinc
IFN-a2b, which unexpectedly exists in the crystal as a
dimer. Structural comparisons of huIFN-a2b with muIFN-b
and other a-helical cytokines identify conformational fea-
tures in huIFN-a2b that are probably critical for receptor
binding. By combining structural analysis with the results of
mutagenesis studies performed on the IFN-a’s, it is possi-
ble to propose putative interaction sites for the known
receptor components of the IFN-a signaling complex.
Results and discussion
Dimeric structure and non-crystallographic symmetry
The crystallographic asymmetric unit contains six copies
of the huIFN-a2b monomer, which form three equivalent
non-covalent dimers with dimensions of 40Å×60Å×20Å
(Fig. 1a,b, Table 1). The monomers in each dimer (dimer
A [molecules 1 and 2], B [molecules 3 and 4], and C 
1454 Structure 1996, Vol 4 No 12
Figure 1
Molecular structure of huIFN-a2b. (a) The
huIFN-a2b dimer viewed approximately parallel
to the twofold axis. (b) View of the huIFN-a2b
dimer perpendicular to the twofold symmetry
axis. The monomers of huIFN-a2b are colored
yellow and green. The zinc ion is represented
as a magenta sphere. (c) Structure of huIFN-
a2b monomer color-coded by secondary
structure: a helices are colored blue, 310
helices magenta and loops yellow. Although
not observed in electron density maps, the
connection between helices C and D is
modeled for completeness.
Table 1
The huIFN-a2b model.
Dimer Molecule Residues modelled
A 1 6–102 112–159
2 8–44 50–102 112–158
B 3 11–44 50–91 112–156
4 8–44 50–96 112–158
C 5 8–44 50–97 112–158
6 10–43 52–92 112–156
[molecules 5 and 6]) are related by an approximate non-
crystallographic twofold axis that runs almost parallel to the
helix bundle. The observed symmetry operations between
the dimer pairs are rotations of 176.6°, 174.3°, 174.4° with
translations along the symmetry axis of 0.2Å, 0.2Å, and
0.1Å for dimers A, B, and C, respectively. The dimer pairs
are related to one another by a pseudo-twofold screw axis
which extends through the asymmetric unit of the crystals.
Structure description
Each monomer of huIFN-a2b (dimensions 40×30×20Å) is
composed of five a-helices, labeled A–E, linked by one
long overhand connection (AB loop) and three short seg-
ments (BC, CD and DE loops). The topology of the mol-
ecule resembles the classical up-up-down-down four-helix-
bundle motif; helices A, B, C, and E comprise the helix
bundle (Fig. 1c). HuIFN-a2b is distinguished from the
classical topology by helix D (consisting of 20 residues)
which replaces the second extended overhand loop (CD
loop) observed in class 1 long chain cytokines [20]. The
presence of a similar length helix (12–19 residues) in the
structures of muIFN-b, IFN-g and IL-10, which each bind
class 2 cytokine receptors, suggests that helix D is a defin-
ing characteristic of the ligands of the class 2 cytokine
receptors. Considerable amino acid sequence homology
between huIFN-a2b and the rest of the IFN-a family sug-
gests that all the other members of this family will have
essentially the same structures (Fig. 2).
Consistent with circular dichroism (CD) measurements,
~68% of the residues in huIFN-a2b adopt helical confor-
mations [24]. The five core a-helices range in length from
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Figure 2
Structure-based sequence alignment of huIFN-a2b and muIFN-b.
Amino acid sequences are shown for huIFN-a2b, huIFN-a1, huIFN-b
and muIFN-b. A consensus sequence (the amino acids most frequently
observed for all huIFN-a sequences) is also shown. Amino acid
residues in bold on the consensus sequence are conserved in all
huIFN-a sequences. Residues in bold in the five sequences are
conserved in all type I interferons. Secondary structure assignments for
huIFN-a2b and muIFN-b are shown above and below the sequences,
respectively. Residues that contribute surface area to the dimer
interface are labeled ‘d’. Residues implicated for biological activity are
highlighted with asterisks (*). The sequences are numbered according
to huIFN-a2b. Letters A–E refer to helices (see Fig. 1c).
13 to 24 amino acids and pack against one another with
crossing angles of 18° to 31°. Each helix is approximately
straight except for helix B which contains a pronounced
bend of 70° centered on Thr69. The extension of helix B
after the bend (residues 70–75, denoted helix B′ in Fig. 1c)
packs against the end of the helix bundle. The disruption
in the a-helical hydrogen-bonding pattern is compensated
for by a network of substitute hydrogen bonds between
the mainchain nitrogens and carbonyl oxygens in the bend
and the sidechain oxygens of Ser68, Thr69, Ser72 and
Tyr85. In addition to Ser72, which participates in the
above interaction, several other polar residues are buried
in the hydrophobic core of the molecule. The buried
groups, which include Ser11, Thr14, Gln91, Tyr122,
Ser150, Ser154, Thr155 and Gln158, form several hydro-
gen bonds that link helices A, C, D, and E in the core. Of
all the buried polar groups, Gln91, Tyr122, Ser150, and
Ser154 are conserved in all human IFN-a amino acid
sequences, but only Tyr122 and Ser154 are conserved in
all vertebrate IFN-a sequences.
The long connection between helices A and B (AB loop) is
structurally diverse and best described in three segments
(AB1: residues 22–33, AB2: residues 34–39 and AB3:
residues 40–51). As observed in other longchain cytokines,
the AB1 loop encircles the N-terminal end of helix E.
Residues 26–29 and 30–33 within the AB1 loop form two
turns of 310 helix (310A, 310B). Cys29 links the 310A helix to
helix E through a disulfide bond with Cys138. Residues on
the 310A and 310B helices include Leu26, Phe27 and Leu30,
displaying solvent-accessible surface areas of 23%, 70%,
and 52%, respectively. The 310B helix precedes the AB2
loop and redirects the mainchain by 90° to run parallel to
the helix bundle. The conformation of the 310B helix allows
three additional interactions with sidechain residues from
helix D. Specifically, the mainchain carbonyl oxygen of
Asp32 hydrogen bonds with the OH of Tyr129 while its
sidechain Od1 and Od2 atoms are sandwiched between the
Nz groups of Lys31 and Lys133. With the exception of
Gly37, which adopts a left handed conformation, the AB2
loop forms an extended structure with Phe36 and Phe38,
inserting into the hydrophobic core of the molecule. Imme-
diately proceeding the AB2 loop, residues 40–43 of the AB3
loop form a third 310 helix (310C). Following the 310C helix,
residues 44–51 link the AB loop into helix B. In contrast to
the long AB loop, the BC and DE loops are short, consisting
of two and four residues, respectively. A notable feature of
the DE loop is the left handed a-helical conformation of
Lys134 and Tyr135.
Five highly flexible regions of huIFN-a2b have been
identified based on missing electron density or high B
factors. For three regions, namely the five N-terminal
residues, the six C-terminal amino acids, and residues
103–111 (the CD loop), no electron density was observed
in any of the six crystallographically independent copies
of the molecule. For one additional segment in the AB3
loop (residues 45–50), weak density (0.6 s) was observed
in molecule 1 only. In this segment Ala50 is an outlier in
the Ramachandran plot indicating that errors may still 
be present in this portion of the loop. All four of these
flexible regions described above are solvent-exposed and
located on one end of the helix bundle. The fifth flexible
region consists of residues 26–31 and is located in the
AB1 loop. In contrast to the other flexible segments,
strong electron density is observed for the AB1 loop in
molecules 2–5, but not in molecules 1 and 6. The absence
of electron density for the AB1 loops of molecules 1 and 
6 correlates with the lack of crystal contacts for these
segments. In contrast, crystal contacts presumably stabi-
lize the AB1 loops in molecules 2–5. This suggests that
although the AB1 loop is held to the N terminus of helix
E by a disulfide bond, it is flexible in solution. Although
it is generally thought that disulfide bonds convey rigid-
ity to protein structures, both of the disulfide bonds 
in huIFN-a2b (Cys1–Cys98 and Cys29–Cys138) are in
regions of high mobility. For residues that could be
placed into electron density, there are no significant
structural differences between the six copies of huIFN-
a2b (Table 2).
The dimer interface
All contacts across the dimer interface are made from
residues on the AB loop and helix D. Residues on these
segments presented to the interface are predominantly
charged and run the entire length of the molecule. This
observation is consistent with the pH-dependent poly-
merization of IFN-a2 [25]. Approximately 1000 Å2 of
surface area is buried in the interface. The most exten-
sive interactions are mediated by a zinc ion which is posi-
tioned on the non-crystallographic symmetry (ncs) dyad
axis. The zinc-binding site is formed from adjacent glu-
tamic acid residues (Glu41 and Glu42) located on the
310C helix. A distorted tetrahedral zinc-coordination
sphere is completed by identical glutamates from the
twofold related molecule (Fig. 3). The unidentate inter-
actions of the Glu41 and Glu42 carboxylate oxygens with
Zn2+ occur in the anti and syn conformations, respectively
[26,27]. The average oxygen-Zn2+ distances for the three
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Table 2
HuIFN-a2b superposition.*
Molecule 1 2 3 4 5 6
1 – 0.39 0.78 0.42 0.44 0.70
2 0.21 – 0.73 0.39 0.35 0.67
3 0.50 0.48 – 0.76 0.77 0.79
4 0.16 0.22 0.52 – 0.40 0.72
5 0.26 0.20 0.48 0.28 – 0.73
6 0.31 0.33 0.39 0.33 0.31 –
*Rms differences (Å) based on residues 11–43, 52–91 and 112–156.
Comparisons are made for Ca atoms (lower left corner) and all atoms
(upper right corner).
metal sites are 1.9 Å (molecules 1,3,5:Glu41(Oε2)–Zn2+),
2.3 Å (molecules 1,3,5:Glu42(Oε2)–Zn2+), 1.9 Å, (mol-
ecules 2,4,6:Glu41 (Oε2)–Zn2+), and 2.2 Å (molecules
2,4,6:Glu42(Oε1)–Zn2+) with maximal deviations from
the mean of 0.1 Å, 0.2 Å, 0.1 Å, and 0.2 Å, respectively. On
either side of the zinc-binding site, two hydrogen bonds
are formed between the Oε1 atom of Gln40 and the NH
of Lys121 and the Od1 atom of Asp114 with the amide
nitrogen of Gly44. From this band of interactions cen-
tered on the 310C helix, the molecules separate at an
angle of ~20°. On the opposite end of the interface, one
potential salt bridge is formed between Arg33 and
Glu132. Because the packing surfaces formed from the
twofold related AB loop and helix D have non-comple-
mentary shapes, the interface contains two buried cavi-
ties. The cavities appear to contain water molecules that
could mediate additional hydrogen bonds across the
interface. However, because only low resolution data are
available, water molecules were not included in the
refined model.
Comparison of IFN-a and IFN-b subspecies
Receptor-binding studies have shown that the human
IFN-a’s and IFN-b compete for the same receptors on
cells [7]. To understand the basis for this competition we
compared the structures of huIFN-a2b and muIFN-b [19]
(Fig. 4a). As previously predicted based on sequence
homology, their overall folds are similar; 116 Ca atoms can
be superimposed with a root mean square (rms) deviation
of 1.5Å. Ca atom positions that differ by more than 2.0Å
occur for residues 6–9 at the N terminus, 22–33 and 40–51
in the AB loop, 69–76 corresponding to the bend in helix
B, and 154–159 at the C terminus. Based on this compari-
son, all type I interferons should display a conserved core
of five helices (excluding the C terminus of helix E) and
the AB2 loop, with structurally distinct regions located on
either end of the helical bundle.
The largest structural difference between IFN-b and the
IFN-a’s is found in the AB1 loop; it contains three more
residues in huIFN-a2b than muIFN-b. The shorter AB1
loop of muIFN-b adopts an extended conformation which
crosses helix E ~5Å further down the helix (towards the C
terminus) than does the AB1 loop of huIFN-a2b. The dif-
ferent crossing position of the AB1 loop on helix E in
huIFN-a2 exposes two highly conserved residues on helix
E (Arg144 and Glu146) to the solvent which could poten-
tially interact with receptor molecules. The AB1 loop of
muIFN-b lacks the two 310 helices that are linked through
a disulfide bond (Cys29–Cys138) to helix E in huIFN-a2b.
Based on sequence analysis, the structural features noted
above should be conserved in other IFN-a molecules.
Compared to the IFN-a’s, the sequence of huIFN-b con-
tains a one-residue deletion (Ser28 in huIFN-a2b) in the
AB1 loop. This deletion, along with significant amino-acid
differences for residues 23–26, may alter the conformation
of a potential 310A helix in huIFN-b. In huIFN-b, the pres-
ence of an equivalent disulfide bond (Cys29–Cys138) and
the conservation of all residues which maintain the confor-
mation of the 310B helix in huIFN-a2b, suggest that the
310B helix found in huIFN-a2b is conserved in huIFN-b.
Residues within the AB3 loop of huIFN-a2b and MuIFN-
b each adopt a turn of 310 helix (310C in huIFN-a2b:
residues 40–43, muIFN-b: residues 41–44) although they
pack with different orientations against the helix bundle.
This difference can be attributed to a 4.5Å-shift in the
position of the Ca atom of Gln40 (Glu40 in MuIFN-b),
which causes a rotation of the helix with respect to the
molecular core. As a result, Gln40, Glu-41, and Glu42 are
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Figure 3
HuIFN-a2b zinc-binding site and dimer
interface. Stereo view of residues 34–43 from
the AB loops of molecules 1 (green) and 2
(gold) in the dimer interface. The zinc ion is
represented as a silver sphere. Electron
density for the protein model (blue) is
calculated with 2Fo–Fc coefficients and
contoured at 1s. Difference density (6 s) for
the zinc ion before its addition to the model is
shown in magenta.
solvent-accesible, whereas Phe43 is buried in huIFN-a2b.
In muIFN-b, Met43, Glu44, and Thr46 are solvent-acces-
sible and Met45 is buried in the core. Analysis of the
amino acid sequences of the type I interferons in light of
this different pattern of exposed and buried residues (e.g.
the fourth residue is buried in the helix in huIFN-a2b
while the third residue is buried in muIFN-b) suggests
that all IFN-a species adopt a 310C helix oriented as in
huIFN-a2b, while huIFN-b is likely to adopt an orienta-
tion similar to muIFN-b. This analysis also suggests that
the structure of the 310C helix of huIFN-a2b is not altered
by the extensive interactions in the dimer. The zinc-
binding residue, Glu42, in huIFN-a2b is replaced by a
hydrophobic residue in the IFN-b sequences. This substi-
tution would probably disrupt the zinc-binding site
observed in huIFN-a2b, but it may be restored by the
additional substitution of Ala118 on helix D with His118
in both murine and human IFN-b. In the crystal structure
of muIFN-b the putative zinc-binding site is occupied by
a water molecule [19].
Helix B in huIFN-a2b is distinguished from muIFN-b by
the presence of a 70° bend centered on Thr69. After the
bend, helix B contains an additional six residues (helix B′)
compared to the extended structure of the BC loop in
muIFN-b. The additional residues used to form helix B′
shorten the extension of the BC loop towards the end of
the helix bundle by ~6Å relative to the loop in muIFN-b.
The polar sidechain residues that make interactions in the
bend of helix B for huIFN-a2b are not conserved in the
human or murine IFN-b sequences (Ser68 is replaced with
arginine, Thr69 is replaced by glutamine or asparagine, and
Tyr85 is replaced by leucine). This suggests that the struc-
ture of huIFN-b is similar to muIFN-b in this region.
A final region of structural divergence between huIFN-a2b
and muIFN-b is found in the C terminus of helix E. Fol-
lowing Ser150, which forms a hydrogen bond with Tyr122,
differences in Ca atom positions are about 1.6Å for
residues 151–153 and increase to 2.5–3.5Å for residues
154– 159. The difference in Ca positions is best described
as a 45° clockwise rotation (looking down the helix axis
from the C terminus) of residues 154–159 in huIFN-a2b
relative to muIFN-b. The different orientations of the 
E helices of huIFN-a2b and muIFN-b appear to be depen-
dent on the interaction made between the residue at posi-
tion 150 in huIFN-a2b (Ser150) and the tyrosine residues
located on helix D. As Ser150 and Tyr122 are conserved 
in all huIFN-a sequences, the orientation of helix E 
in huIFN-a2b is likely to be present in all huIFN-a
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Figure 4
Comparisons of the structure of huIFN-a2b
with other cytokines. (a) Stereo view a-carbon
atom superposition of huIFN-a2b (magenta)
and muIFN-b (gold). The Cys29–Cys138
disulfide bond is shown in cyan. (b) Stereo
view a-carbon atom superposition of huIFN-
a2b (magenta), IL-10 (gold), and IFN-g (blue).
Only one domain of the IL-10 and IFN-g
dimers is shown. 
molecules. Similarly, the conservation of Asn148 (equiva-
lent to Ser150 in huIFN-a2) and Tyr120 and Tyr121
(muIFN-b numbering) in murine and human IFN-b, sug-
gests that the structure of helix E in huIFN-b is similar to
muIFN-b. It is interesting that Arg144, Glu146 and
Arg149, which are conserved in all known type I interfer-
ons, are located on helix E prior to the structural diver-
gence of helix E.
Structural comparison with other helical cytokines
We made additional structural comparisons between
huIFN-a2b and other a-helical cytokine structures (Fig.
4b). Consistent with their common classification as class 2
cytokines, the best overall structural similarity (excluding
muIFN-b) of huIFN-a2b is with IL-10 (102 equivalent Ca
atoms, rms deviation of 2.2Å). A more limited similarity is
observed within the class 1 long chain cytokines, where the
number of equivalent atoms ranged from 86 (rms deviation
of 2.0Å) for growth hormone (GH) to 75 atoms (rms devia-
tion of 1.9Å) for leukemia inhibitory factor (LIF). These
comparisons reveal a relatively well conserved four-helix
bundle for all of the longchain cytokines, whereas the
mainchain positions of the long overhand loops of the class
1 cytokines differ considerably from the class 2 molecules.
One exception occurs for GH, where a general structural
correspondence is found for residues equivalent to the AB1
loop in huIFN-a2b although, the mainchain deviates con-
siderably from that of huIFN-a2b in the AB2 and AB3 por-
tions of the loop. In contrast to the high structural similarity
between huIFN-a2b and IL-10, the overall structure align-
ment of huIFN-a2b and IFN-g is very poor. However, helix
A, the AB loop and helix F from IFN-g can be overlaid
onto helix A, the AB loop, and helix E of huIFN-a2b with
an rms deviation of 2.3Å for 59 residues. For all three
human class 2 cytokine structures (huIFN-a2b, IFN-g, and
IL-10), the AB loop which encircles the C-terminal helix is
flexible [21,28,29]. The recent crystal structure of IFN-g
complexed with its high affinity receptor showed that this
flexible loop adopts a 310 helical conformation upon a direct
interaction with its receptor [12]. The location of this 310
helix in IFN-g corresponds to that of the 310B helix in
huIFN-a2b. Also conserved in the huIFN-a2b/IFN-g struc-
ture alignment is the position of a glutamic acid (Glu146 in
huIFN-a2b, Glu112 in IFN-g), which in IFN-g is known to
directly interact with the IFN-g receptor. Although consid-
erable structural similarity is observed in the AB loop
regions of huIFN-a2b, IFN-g and IL-10, there are signifi-
cant structural differences in the regions corresponding to
the BC and DE loops of huIFN-a2b.
Residues affecting biological activity
There are several amino acid residues in IFN-a for which
mutations are known that change the biological activity of
the protein by more than fivefold. These include Leu30,
Lys31, Arg33, His34, Phe36, Arg120, Lys121, Gln124,
Tyr122, Tyr129, Lys131, and Glu132 [30,31]. Of these
residues, Arg33 is especially sensitive to amino acid substi-
tutions; this is reflected in the 500 and 2500 fold drop in
activity in the Arg33→Lys and Arg33→Ala mutants,
respectively [32]. Additional residues reported to cause
large reductions in biological activity are Arg144 [19], and
Glu146 [33]. The inclusion of Arg144 as an important
residue is based on the loss of activity reported for the
Arg144 to Ala144 mutant of huIFN-b. In addition to muta-
genesis studies, a 50-fold activity loss was observed for the
IFN-a1/IFN-a2 hybrid molecule which differs from
huIFN-a2b at three positions: Arg22→Ser, Leu26→Pro,
and Phe27→Ser [34]. Additional hybrid studies found that
sequence differences between IFN-a1 and IFN-a2 at posi-
tions Ser68, Thr79, and Tyr85 of huIFN-a2b caused a
reduction of IFN-a2 activity on human cells while simulta-
neously increasing its activity on murine cells [35]. Simi-
larly, using IFN-a1/IFN-a8 chimeras, Lys83 and Tyr89
were shown to make direct interactions with the IFN-aR1
[36]. In contrast to residues which alter biological activity,
changes to Phe47, Gln48, or Gln61, or the deletion of
residues 1–4, 102–111, or 156–165 have no effect on the
antiviral activity of IFN-a2 [37–39].
The locations of these important residues on huIFN-a2b
are shown in Figure 5. Based on the structure of huIFN-
a2b, Phe36, Tyr122 and Tyr129 are buried in the molecular
core and are presumably important for the structural
integrity of the protein. The rest of the residues implicated
in receptor binding and biological activity are located on
the AB loop (Arg22, Leu26, Phe27, Leu30, Lys31, Arg33,
His34), the bend in helix B (Ser68) and helices C (Thr79,
Lys83, Tyr85, and Tyr89), D (Arg120, Lys121, Gln124,
Lys131, and Glu132) and E (Arg144, and Glu146). These
‘active’ regions of IFN-a are all located at one end of the
helix bundle. The AB1 loop, (the region that is most sensi-
tive to amino-acid replacement) and helix C (which has
been implicated in binding to the IFN-aR1) are located on
opposite sides of the molecule and probably form two dis-
tinct receptor-binding sites.
The two regions of huIFN-a2b identified by mutagenesis
as critical for biological activity are found in positions
similar to the receptor-binding sites defined in the crystal
structures of the GH and IFN-g receptor–ligand com-
plexes [12,40]. In GH and IFN-g, the high affinity recep-
tor-binding site (site 1) consists of residues on helix A, the
AB loop and the C-terminal helix (helix E in huIFN-a2b),
while in GH a second site (site 2) is formed from different
residues on helix A and helix C. Consistent with the struc-
tural similarities between IFN-g and huIFN-a2b, the site 1
binding surface of huIFN-a2b would include the AB loop,
helix E (up to Asn156) and possibly residues on helix A
(currently no residues on the helix have been identified as
important for binding by mutagenesis). The electrostatic
potential of this surface is predominantly neutral except for
three highly conserved arginine residues (Arg33, Arg144,
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and Arg149) and Glu146. These four residues, which are
implicated in receptor binding, are conserved amongst all
type I interferons, as are the residues that stabilize the con-
formation of the AB loop (Cys29–Cys138, Phe36, Tyr122,
Arg125 and Tyr129). Based on the high sequence conser-
vation of site 1 between the human IFN-a’s and IFN-b,
the IFN-a/bR (and/or possibly another, as yet unidenti-
fied, receptor) may bind at this site. It seems likely from
the hybrid data, that the IFN-aR1 would interact with
huIFN-a2b at a site analogous to site 2 of GH as defined in
the GH-receptor complex. Unlike site 1, which is well con-
served, the huIFN-a2b residues implicated in binding to
the IFN-aR1 (residue positions 79, 83, 85, and 89) are the
amino acids on helix C that are least conserved among the
IFN-a family. Similar sequence variations are observed for
the adjacent helices A and B which probably also con-
tribute residues to receptor binding site 2.
Clearly, this two-site model does not explain all of the 
IFN-a structure–function data. Specifically, the model 
fails to explain how residues of helix D that are important
for biological activity interact with a receptor molecule. It
has been suggested that helix D and the AB-loop form one
continuous binding surface [19]. But the crystal structure
shows that the relevant residues on the AB1 loop and helix
D are located on opposite sides of huIFN-a2b, and so are
unlikely to form a single receptor-binding surface. As an
alternative model, we propose that the IFN-aR1 makes two
contacts with IFN-a. This could be accomplished using 
the two putative cytokine-binding domains displayed by 
IFN-aR1. The membrane proximal domain would interact
with helices A and C (site 2), while the N-terminal domain
would bind residues on helix D (site 3). Similar models
have been previously proposed for LIF [41] and ciliary 
neurotrophic factor [42] which each share multidomain
receptors. It is interesting that this apparent discrepancy is
avoided if the receptors interact with an huIFN-a2b dimer.
Further high resolution epitope mapping studies with puri-
fied receptor components are necessary to evaluate the
accuracy of this model.
Functional role of the dimer
The structure of huIFN-a2b reveals yet another unique
mode of dimer association for a-helical cytokines. In con-
trast to the structures of IFN-g [21], IL-10 [29,43], IL-5
[44], and macrophage colony-stimulating factor [45], which
are known to function as dimers, the biological role of the
huIFN-a2b dimer is unknown. Gel filtration studies at
physiological conditions (phosphate buffered saline [PBS],
pH7.4) demonstrate that huIFN-a2b is monomeric at
concentrations of up to 50mM (data not shown). Further-
more, although zinc is observed in the huIFN-a2b dimer
interface, addition of up to 1mM zinc in gel filtration
experiments does not shift the monomer–dimer equilib-
rium towards the dimer. These experiments, as well as the
extremely low concentrations of huIFN-a2b required for in
vivo activity, suggest that the active form of huIFN-a2b 
is monomeric.
Consistent with the work of Shire [25], the monomer–
dimer aggregation state of huIFN-a2b is highly dependent
on ionic strength, as would be expected given the high
concentration of charge at the dimer interface. At low ionic
strength (20mM Tris, pH7.5, 100mM NaCl), huIFN-a2b
forms a dimer at concentrations of 20µM. This may allow
huIFN-a2b to exist in a storage form analogous to the 
GH zinc dimer [46], which is inactive because several
residues which form direct interactions with the GH
receptor are buried in the dimer interface. In contrast, in
the huIFN-a2b dimer only Glu41 and Glu42 (which form
the zinc-binding site) are completely buried in the inter-
face, while His34 is partially occluded. The other residues
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Figure 5
Stereo view of IFN-a residues that appear to
be important for biological activity. Single
residue mutations which alter biological
activity are shown in red. Sidechain residues
in green represent single mutations that are
important in maintaining the structural integrity
of the molecule. Simultaneous mutations
which affect biological activity are grouped by
color. These consist of the residue clusters
Arg22, Leu26, Phe27 (yellow); Ser68, Thr79,
Tyr85 (orange); Lys83, Tyr89 (cyan); Arg120,
Lys121 (gray); and Lys133, Lys134
(magenta). The mainchain for residues
102–112 and 156–160, which do not effect
biological activity are shown as a green
ribbon. Residues 103–111 were not observed
in the structure and are modeled to provide
their general position. Residues are numbered
according to the huIFN-a2b sequence.
believed to be important for the biological activity of
IFN-a are located on the exterior surfaces of the dimer,
where they are accessible for receptor binding. Although
current experiments suggest that it is unlikely that the
huIFN-a2b dimer participates in the active recruitment of
receptor subunits to the IFN-a signaling complex, more
studies must be completed to prove this. It is possible that
conditions at the receptor surfaces may favor the formation 
of the huIFN-a2b dimer which can clearly exist under
certain in vitro conditions. If we assume that the dimer 
is the ‘active’ species, there is no need for a distinct recep-
tor-binding site (site 3) on helix D as proposed above. 
In the dimer, the close proximity of helix D to the AB 
loop would allow the formation of one continuous con-
served binding surface at site 1 as proposed by Senda et al.,
[19]. Since the residues that can form the specific interac-
tions in the dimer interface are conserved in all human
IFN-a’s, mixed dimers would be possible, allowing
further modulation of IFN-a activity. Further experimen-
tation to elucidate the biological role of the huIFN-a2b
dimer will be facilitated by the determination of its three-
dimensional structure.
Biological implications
The human a-interferons (huIFN-a’s) are composed 
of at least 15 different, but closely related amino acid
sequences and have distinct antiviral, immunomodula-
tory and cytostatic effects on a variety of cell types. These
important biological activities are stimulated through the
specific high affinity interactions of the IFN-a’s with
their cell-surface receptors. The 2.9Å crystal structure of
huIFN-a2b provides a basis for understanding how the
structural differences between different members of the
IFN-a family affect biological activity.
The topology of huIFN-a2b resembles the classical up-
up-down-down four-helix bundle motif observed for
other ligands of the class 1 and class 2 cytokine recep-
tors. The fold of huIFN-a2b may be grouped with other
cytokines which bind to class 2 cytokine receptors
(IFN-a, IFN-b, IFN-g and IL-10) by the presence of 
a fifth helix in the molecular core. This helix replaces
the extended overhand loop (CD loop) first observed in
the structure of growth hormone. Further comparisons
of huIFN-a2b with other a-helical cytokines revealed
the greatest structural similarity with IFN-b and IL-10.
Previous site directed mutagenesis data has been used to
determine which residues are important for biological
activity. The structure of huIFN-a2b reveals which of
these are likely to be structurally important, and which
are solvent accessible and therefore likely to interact
directly with receptor molecules.
Unexpectedly, huIFN-a2b exists in the crystal as a dimer.
Interactions in the dimer interface are stabilized predomi-
nantly through a zinc ion giving rise to a novel mode of
subunit association not previously observed for other
cytokines. The biological role of the dimer is currently
unknown, although experimental evidence to date sug-
gests the active species of huIFN-a2b is monomeric. The
dimer may serve as an inactive storage form of the mol-
ecule, or be important in as yet undetermined ways of
recruiting the various IFN-a receptors to the signaling
complex. The structure of huIFN-a2b provides a basis for
further biochemical studies aimed at understanding the
receptor–ligand interactions for this biologically important
family of molecules.
Materials and methods
Crystallization
Crystals of recombinant huIFN-a2b were grown using the hanging drop
vapor diffusion method. The protein drops, consisting of 1ml of recombi-
nant human IFN-a2b solution (40mgml–1), were mixed with 1ml of the
reservoir solution (40mM ZnAc2, 30mM cacodylate, pH5.6) and equili-
brated at 23°C. These experiments produced intergrown aggregates
which were crushed with a needle. The needle was then streaked across
new protein drops which had been equilibrated at 4°C for 6h. Following
streak seeding, the crystallization trays were transferred to a 13°C incu-
bator. After several days, a number of small perfect crystals grew along
the needle trail. The seed crystals were transferred into fresh protein
drops (4ml+4ml drops) and returned to the 13°C incubator. The crys-
tals reached maximum dimensions of 0.5mm×0.5mm×0.3mm within
two weeks. The crystals belong to the monoclinic space group P21 with
unit cell dimensions a=62.4Å, b=75.5Å, c=148.2Å, and b=90.8°.
The crystallographic asymmetric unit contains six molecules of huIFN-a2b
which corresponds to a solvent content of ~60%.
Structure determination
The structure of huIFN-a2b was elucidated using a combination of multi-
ple isomorphous replacement (MIR) and symmetry averaging tech-
niques. X-ray intensity data were collected on an R-axis IIC image plate
detector mounted on a Rigaku RU-200 rotating anode generator (CuKa
radiation) operating at 100mA and 40kV. The data were integrated and
scaled using the programs provided by Molecular Structure Corporation.
All native and derivative data sets were collected at –170°C (Table 3).
Almost all data manipulations were carried out using the CCP4  suite 
of programs [47]. Two derivatives of huIFN-a2b (K2Pt(NO2)4, and
K2UO2Ac2) were identified by difference Patterson analysis of the heavy-
atom data. Refinement of the heavy-atom parameters and subsequent
phase calculations were carried out in MLPHARE [48]. Calculation of a
5Å electron-density map revealed a well defined protein–solvent bound-
ary that outlined the position of six clusters of rod-shaped density, where
each cluster resembled a four helix bundle. Using computer graphics,
a-carbon atoms of muIFN-b (PDB entry,1rmi) were fitted into each of the
six density clusters. The fitted coordinates were used to obtain initial non-
crystallographic symmetry (ncs) matrices relating the six molecules of
huIFN-a2b to each other. Molecular envelopes for symmetry averaging the
six huIFN-a2b molecules were constructed with MAMA [49]. Optimization
of the ncs operators was done using the IMP option of the RAVE
program suite [50]. Sixfold symmetry averaging combined with solvent
leveling produced exceptionally clear and continuous 3Å electron density
for model building, while unaveraged MIR maps were uninterpretable.
Phase refinement using solvent leveling, histogram matching, and sixfold
symmetry averaging were accomplished using the program DM [51].
Using the symmetry averaged map, residues 10–46, 53–96 and
113–156 were aligned into the density using CHAIN [52] and TURBO-
FRODO [53]. Confidence in the peptide-chain tracing was obtained from
the well defined density observed for Trp76 and Trp140 as well as the
Cys29–Cys138 disulfide bond. The other five molecules of huIFN-a2b
were placed into the asymmetric unit using the ncs operators.
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The structure of huIFN-a2b was refined with the program X-PLOR [54]
using the stereochemical parameter files defined by Engh and Huber
[55]. A randomly selected 5% of the data were removed prior to refine-
ment for analysis of the free R factor [56]. The initial R factor for the six
molecules consisting of residues 10–43, 53–96, and 113–156 was
32.0 % (Rfree = 42.0 %). The progress of further refinements were moni-
tored by the decrease in both the conventional and free R factor values.
Residue segments restrained by the ncs symmetry include 12–15,
17–42, 51–63, 65–84 and 114–155. The ncs weight of 30
kcal mol–1 Å–2 was used for all segments based on the analysis of the
free R factor over multiple refinement runs where the ncs weight was
varied. Additionally, two temperature factors, one for mainchain atoms,
and one for sidechain atoms, were refined for each residue in the
model. The current model is comprised of 6476 non-hydrogen atoms
and four zinc ions. The R factor is 22.7% (22.2 %, F>2s) with an Rfree
of 31.3 % (30.4 % for F > 2(F) for all data at 6–2.9Å [27 021 reflec-
tions]). No solvent molecules have been added to the model. The rms
deviations from ideal bond lengths and angles are 0.015Å and 1.97°,
respectively. With the exception of Ala50, all residues are located in
allowed regions of φ,ψ, space with >90% in the most favored region of
the Ramachandran plot. The average temperature factor for the six IFN-
a2b monomers ranges from 22.6Å2 to 37.8 Å2.
The improvement in the stereochemical parameters of the model were
followed using PROCHECK [57]. Model superpositions were defined
manually using the computer graphics and improved using the least
squares procedure in O [58]. Figures 1, 3, 4 and 5 were made with the
program package RIBBONS [59].
Accession numbers
Atomic coordinates have been deposited in the protein data bank (Acces-
sion number 1RH2).
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